Close Menu

NEW YORK – Aethlon Medical announced on Monday that it has received a $1.9 million award from the National Cancer Institute.

The two-year, Small Business Innovation Research (SBIR) Phase 2 contract will fund development and optimization of Aethlon's Hemopurifier, a benchtop device that isolates exosomes from biofluids for applications in cancer research and clinical care.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.